Susquehanna Portfolio Strategies’s Arcus Biosciences RCUS Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Sell	53,668 -186,298	-78%	-$4.6M	0.03%	471
2026 Q1	$5.18M	Hold	239,966	–	–	0.08%	296
2025 Q4	$5.72M	Hold	239,966	–	–	0.09%	291
2025 Q3	$3.26M	Sell	239,966 -8,000	-3%	-$83.2K	0.05%	394
2025 Q2	$2.02M	Buy	+247,966	New	+$2.12M	0.04%	370
2024 Q1	–	Sell	-34,432	Closed	-$658K	–	922
2023 Q4	$658K	Buy	+34,432	New	+$550K	0.01%	703

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Susquehanna Portfolio Strategies's RCUS Position: Q2 2026 in Review

Susquehanna Portfolio Strategies reduced its Arcus Biosciences (RCUS) stake by 78% in Q2 2026, selling an estimated $4.6M and leaving 53,668 shares worth $1.65M. The position accounts for 0.03% of the portfolio, ranked #471.

Susquehanna Portfolio Strategies first reported a position in RCUS in Q4 2023 and has held it in 6 quarters since. The position peaked at $5.72M in Q4 2025. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Susquehanna Portfolio Strategies held 53,668 shares of Arcus Biosciences worth $1.65M as of Q2 2026.
Susquehanna Portfolio Strategies sold 186,298 Arcus Biosciences shares in Q2 2026, an estimated $4.6M.
Arcus Biosciences made up 0.03% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #471 holding.
Susquehanna Portfolio Strategies first reported a position in Arcus Biosciences in Q4 2023 and has held it in 6 quarters since.
Susquehanna Portfolio Strategies's Arcus Biosciences position peaked at $5.72M in Q4 2025.
231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.